Longeveron’s (LGVN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Longeveron’s Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.20) EPS.

A number of other analysts have also weighed in on LGVN. Roth Capital upgraded Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm initiated coverage on Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 target price for the company.

Longeveron Stock Performance

Shares of NASDAQ:LGVN opened at $1.40 on Monday. Longeveron has a twelve month low of $0.77 and a twelve month high of $6.40. The firm has a market cap of $20.77 million, a PE ratio of -0.22 and a beta of 0.36. The business has a fifty day moving average of $1.64 and a 200-day moving average of $1.89.

Hedge Funds Weigh In On Longeveron

Several hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Longeveron in the fourth quarter valued at about $35,000. Northern Trust Corp bought a new position in Longeveron in the fourth quarter valued at about $31,000. Virtu Financial LLC bought a new position in Longeveron in the fourth quarter valued at about $53,000. Geode Capital Management LLC boosted its holdings in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the last quarter. Finally, State Street Corp bought a new position in Longeveron in the third quarter valued at about $29,000. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.